

Breakthrough Therapy (BT) Designation-Europe Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/B59905AD8A7MEN.html

Date: May 2018

Pages: 149

Price: US\$ 3,480.00 (Single User License)

ID: B59905AD8A7MEN

Abstracts

Report Summary

Breakthrough Therapy (BT) Designation-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Breakthrough Therapy (BT) Designation industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Breakthrough Therapy (BT) Designation 2013-2017, and development forecast 2018-2023

Main market players of Breakthrough Therapy (BT) Designation in Europe, with company and product introduction, position in the Breakthrough Therapy (BT) Designation market

Market status and development trend of Breakthrough Therapy (BT) Designation by types and applications

Cost and profit status of Breakthrough Therapy (BT) Designation, and marketing status Market growth drivers and challenges

The report segments the Europe Breakthrough Therapy (BT) Designation market as:

Europe Breakthrough Therapy (BT) Designation Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany



United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Breakthrough Therapy (BT) Designation Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Oncology

Infectious Diseases

Rare Diseases

Autoimmune Diseases

Pulmonary Diseases

Neurological Disorders

Others

Europe Breakthrough Therapy (BT) Designation Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital

Clinic

Research Institute

Laboratories

Europe Breakthrough Therapy (BT) Designation Market: Players Segment Analysis (Company and Product introduction, Breakthrough Therapy (BT) Designation Sales Volume, Revenue, Price and Gross Margin):

Roche

Abbvie

Novartis International AG

Janssen

BMS

Eli Lilly

Gilead



Regeneron

Acadia

Boehringer Ingelheim

Amgen

AstraZeneca

GlaxoSmithKline

Vertex

Alexion

Merck

Jazz Pharmaceuticals

Exelixis

Eisai

Takeda

Pfizer

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF BREAKTHROUGH THERAPY (BT) DESIGNATION

- 1.1 Definition of Breakthrough Therapy (BT) Designation in This Report
- 1.2 Commercial Types of Breakthrough Therapy (BT) Designation
 - 1.2.1 Oncology
 - 1.2.2 Infectious Diseases
 - 1.2.3 Rare Diseases
 - 1.2.4 Autoimmune Diseases
 - 1.2.5 Pulmonary Diseases
 - 1.2.6 Neurological Disorders
- 1.2.7 Others
- 1.3 Downstream Application of Breakthrough Therapy (BT) Designation
 - 1.3.1 Hospital
 - 1.3.2 Clinic
 - 1.3.3 Research Institute
 - 1.3.4 Laboratories
- 1.4 Development History of Breakthrough Therapy (BT) Designation
- 1.5 Market Status and Trend of Breakthrough Therapy (BT) Designation 2013-2023
- 1.5.1 EMEA Breakthrough Therapy (BT) Designation Market Status and Trend 2013-2023
- 1.5.2 Regional Breakthrough Therapy (BT) Designation Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Breakthrough Therapy (BT) Designation in EMEA 2013-2017
- 2.2 Consumption Market of Breakthrough Therapy (BT) Designation in EMEA by Regions
- 2.2.1 Consumption Volume of Breakthrough Therapy (BT) Designation in EMEA by Regions
- 2.2.2 Revenue of Breakthrough Therapy (BT) Designation in EMEA by Regions
- 2.3 Market Analysis of Breakthrough Therapy (BT) Designation in EMEA by Regions
 - 2.3.1 Market Analysis of Breakthrough Therapy (BT) Designation in Europe 2013-2017
- 2.3.2 Market Analysis of Breakthrough Therapy (BT) Designation in Middle East 2013-2017
 - 2.3.3 Market Analysis of Breakthrough Therapy (BT) Designation in Africa 2013-2017
- 2.4 Market Development Forecast of Breakthrough Therapy (BT) Designation in EMEA



2018-2023

- 2.4.1 Market Development Forecast of Breakthrough Therapy (BT) Designation in EMEA 2018-2023
- 2.4.2 Market Development Forecast of Breakthrough Therapy (BT) Designation by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
- 3.1.1 Consumption Volume of Breakthrough Therapy (BT) Designation in EMEA by Types
- 3.1.2 Revenue of Breakthrough Therapy (BT) Designation in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Breakthrough Therapy (BT) Designation in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Breakthrough Therapy (BT) Designation in EMEA by Downstream Industry
- 4.2 Demand Volume of Breakthrough Therapy (BT) Designation by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Breakthrough Therapy (BT) Designation by Downstream Industry in Europe
- 4.2.2 Demand Volume of Breakthrough Therapy (BT) Designation by Downstream Industry in Middle East
- 4.2.3 Demand Volume of Breakthrough Therapy (BT) Designation by Downstream Industry in Africa
- 4.3 Market Forecast of Breakthrough Therapy (BT) Designation in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BREAKTHROUGH THERAPY (BT) DESIGNATION

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Breakthrough Therapy (BT) Designation Downstream Industry Situation and Trend



Overview

CHAPTER 6 BREAKTHROUGH THERAPY (BT) DESIGNATION MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Breakthrough Therapy (BT) Designation in EMEA by Major Players
- 6.2 Revenue of Breakthrough Therapy (BT) Designation in EMEA by Major Players
- 6.3 Basic Information of Breakthrough Therapy (BT) Designation by Major Players
- 6.3.1 Headquarters Location and Established Time of Breakthrough Therapy (BT) Designation Major Players
- 6.3.2 Employees and Revenue Level of Breakthrough Therapy (BT) Designation Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 BREAKTHROUGH THERAPY (BT) DESIGNATION MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Roche
 - 7.1.1 Company profile
 - 7.1.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.1.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Roche
- 7.2 Abbvie
 - 7.2.1 Company profile
 - 7.2.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.2.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Abbvie
- 7.3 Novartis International AG
 - 7.3.1 Company profile
 - 7.3.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.3.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Novartis International AG
- 7.4 Janssen
 - 7.4.1 Company profile
 - 7.4.2 Representative Breakthrough Therapy (BT) Designation Product
 - 7.4.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross



Margin of Janssen

- **7.5 BMS**
 - 7.5.1 Company profile
 - 7.5.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.5.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of BMS
- 7.6 Eli Lilly
 - 7.6.1 Company profile
 - 7.6.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.6.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.7 Gilead
 - 7.7.1 Company profile
 - 7.7.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.7.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Gilead
- 7.8 Sanofi
 - 7.8.1 Company profile
 - 7.8.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.8.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Sanofi
- 7.9 Regeneron
 - 7.9.1 Company profile
 - 7.9.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.9.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Regeneron
- 7.10 Acadia
 - 7.10.1 Company profile
- 7.10.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.10.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Acadia
- 7.11 Boehringer Ingelheim
 - 7.11.1 Company profile
 - 7.11.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.11.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
- 7.12 Amgen
 - 7.12.1 Company profile
- 7.12.2 Representative Breakthrough Therapy (BT) Designation Product



- 7.12.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Amgen
- 7.13 AstraZeneca
 - 7.13.1 Company profile
 - 7.13.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.13.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of AstraZeneca
- 7.14 GlaxoSmithKline
 - 7.14.1 Company profile
 - 7.14.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.14.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 7.15 Vertex
 - 7.15.1 Company profile
 - 7.15.2 Representative Breakthrough Therapy (BT) Designation Product
- 7.15.3 Breakthrough Therapy (BT) Designation Sales, Revenue, Price and Gross Margin of Vertex
- 7.16 Alexion
- 7.17 Merck
- 7.18 Jazz Pharmaceuticals
- 7.19 Exelixis
- 7.20 Eisai
- 7.21 Takeda
- 7.22 Pfizer

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BREAKTHROUGH THERAPY (BT) DESIGNATION

- 8.1 Industry Chain of Breakthrough Therapy (BT) Designation
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BREAKTHROUGH THERAPY (BT) DESIGNATION

- 9.1 Cost Structure Analysis of Breakthrough Therapy (BT) Designation
- 9.2 Raw Materials Cost Analysis of Breakthrough Therapy (BT) Designation
- 9.3 Labor Cost Analysis of Breakthrough Therapy (BT) Designation
- 9.4 Manufacturing Expenses Analysis of Breakthrough Therapy (BT) Designation



CHAPTER 10 MARKETING STATUS ANALYSIS OF BREAKTHROUGH THERAPY (BT) DESIGNATION

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Breakthrough Therapy (BT) Designation-Europe Market Status and Trend Report

2013-2023

Product link: https://marketpublishers.com/r/B59905AD8A7MEN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/B59905AD8A7MEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



